The UK market for peptides labelled “for laboratory use only” or “for research use only” (RUO) has become an increasingly complex regulatory area. Once largely confined to academic and industrial research settings, many peptides are now marketed online despite growing concerns that they are ultimately intended for human consumption. This has attracted increasing attention from the Medicines and Healthcare products Regulatory Agency (MHRA), media outlets, and enforcement authorities.
For Regulatory Affairs professionals, peptides present a fascinating case study in medicines legislation, borderline products, intended use, and regulatory enforcement. The central question is often not whether a peptide is pharmacologically active, but whether the way it is presented, marketed, and supplied causes it to become a medicinal product under UK law.
Why are research peptides in the spotlight?
Over the last few years, the peptide market has expanded significantly, driven by interest in weight management, sports performance, anti-ageing and wellness products. Compounds such as BPC-157, TB-500, retatrutide and other GLP-1 related peptides have featured prominently in online discussions and media reports.
Recent MHRA enforcement activity has focused on unlicensed medicinal products, particularly injectable weight-loss medicines and peptide products marketed with health-related claims. Media investigations have also highlighted UK suppliers selling peptides under a “research use only” disclaimer while appearing to target consumers seeking therapeutic outcomes.
The increased regulatory scrutiny reflects concerns around:
- Product quality and sterility.
- Lack of clinical evidence.
- Patient safety risks.
- Unlicensed medicines supply.
- Misleading promotional practices.
- Circumvention of medicines legislation through research-only disclaimers.
For regulators, the concern is that an RUO label cannot simply be used as a shield when the overall presentation suggests human use.
What makes something a medicine?
The starting point is the Human Medicines Regulations 2012 (HMRs). Regulation 2 of HMR 2012 defines a medicinal product by virtue of its presentation and/or function:
Any substance or combination of substances presented as having properties of preventing or treating disease in human beings. (Presentational limb)
Or:
Any substance or combination of substances that may be used by or administered to human beings with a view to restoring, correcting or modifying physiological functions by exerting a pharmacological, immunological or metabolic action, or making a medical diagnosis. (Functional Limb)
A product only needs to satisfy one of these definitions to be considered a medicinal product, and this distinction is particularly important when considering peptides.
The MHRA’s Borderline products approach
The MHRA recognises that some products sit between established regulatory categories such as:
- Medicines
- Medical devices
- Food supplements
- Cosmetics
- Biocides
- Laboratory products.
These are known as borderline products. In its updated guidance on borderline products and MHRA Guidance Note 8, the agency emphasises that classification is determined on a case-by-case basis. Factors considered include:
- Claims made about the product
- Intended purpose
- Active ingredients
- Mode of action
- Product presentation
- Consumer perception.
Importantly, the MHRA does not assess promotional claims in isolation. It may also consider:
- Website content
- Product imagery
- Customer testimonials
- Social media marketing
- Associated educational materials
- Product naming conventions.
Consequently, a peptide marketed as a research reagent may nevertheless be regarded as a medicinal product if the overall presentation implies therapeutic use.
Why “Research Use Only” does not necessarily excuse suppliers
One of the most misunderstood aspects of this area is the role of RUO disclaimers.
Many peptide suppliers prominently display statements such as: “For laboratory research only”, “Not for human consumption” or “Research chemical”. While these statements may be relevant, they are not determinative.
The MHRA’s approach focuses on substance over form. A disclaimer may carry little weight if other aspects of the marketing indicate that the supplier anticipates or encourages human use.
Examples of factors that may trigger regulatory concern include:
- References to weight loss
- References to performance enhancement
- Discussion of therapeutic effects
- Dose-strength presentations resembling medicinal products
- Injectable product formats
- Testimonials describing health outcomes
- Links to administration protocols.
A supplier cannot simultaneously claim a product is for laboratory use while providing information that effectively promotes medicinal use.
Peptides and the functional limb
Even in the absence of explicit medicinal claims, peptides frequently raise questions under the functional limb of the definition. Many peptides are biologically active and are designed to interact with specific receptors or physiological pathways. These can include GLP-1 receptor agonists, Growth hormone releasing peptides, Tissue repair peptides and Immunomodulatory peptides.
The MHRA may therefore consider whether the pharmacological action itself is sufficient to bring a product within medicines legislation. Although each case is assessed individually, the more significant and targeted the biological activity, the stronger the potential argument that the product functions as a medicinal product. This is particularly relevant for novel peptides that closely resemble authorised medicinal substances or compounds undergoing clinical development.
What should regulatory affairs professionals consider?
For regulatory professionals advising clients, investors, manufacturers or distributors, several key questions should be asked.
1. What is the intended use?
The intended purpose remains fundamental. It should be considered: Who is the target user?
How is the product being supplied? What does the supplier expect purchasers to do with it? Documented evidence supporting legitimate laboratory use can be important.
2. Review the Entire Promotional Ecosystem
Do not assess only the product label, but also review website copy, blogs, FAQs, social media channels, email campaigns, Influencer activity and search engine advertising. The cumulative impression may be more significant than any individual statement.
3. Evaluate Presentation Risk
Ask whether the product resembles a medicinal product. Potential risk indicators include sterile injectable formats, pharmaceutical packaging, dose strengths, claims regarding physiological effects.
4. Consider MHRA Borderline Advice
Where uncertainty exists, formal advice from the MHRA may be appropriate. The Medicines Borderline Advice process can help companies understand how the agency is likely to classify a product before substantial commercial investment is made.
5. Assess Exposure Beyond Medicines Legislation
Regulatory implications may extend beyond the MHRA. Potential considerations include:
- CAP Code advertising requirements
- Trading Standards enforcement
- Consumer protection legislation
- UK Anti-Doping considerations
- Importation and supply chain controls
- Product liability exposure.
Conclusion
The UK peptide market highlights a broader regulatory principle: classification depends not only on what a product is, but on how it is presented, perceived and intended to be used.
For Regulatory Affairs professionals, peptides sold for laboratory use represent a classic borderline product challenge. While genuine research reagents may sit outside medicines regulation, the addition of medicinal claims, implied therapeutic use, or pharmaceutical-style presentation can quickly shift a product into the scope of the Human Medicines Regulations.
As MHRA scrutiny continues to increase, regulatory teams should adopt a holistic assessment of peptide products, considering not only the active substance but also the wider commercial context. In this area, “research use only” is not a regulatory strategy. Careful evaluation of claims, presentation and intended use remains the most effective way to navigate the boundary between research products and medicines.
If you would like to discuss how Fusion Pharma can support you further, please email us at hello@fusion-pharma-limited.com or phone us on +44 (0) 203 1379 799.
While the information in this article is considered to be true and correct at the date of publication, changes in guidance and/or experience may impact on the accuracy of the information. Please refer to the relevant guidance for the latest information.